Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71332-0006-90 71332-0006 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral June 24, 2024 In Use
23155-0777-71 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0777-72 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
00703-4155-11 00703-4155 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 1, 2002 Aug. 31, 2023 No Longer Used
00703-4155-91 00703-4155 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 1, 2002 Jan. 31, 2013 No Longer Used
63020-0078-01 63020-0078 Ixazomib Ninlaro 2.3 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 No Longer Used
63020-0078-02 63020-0078 Ixazomib Ninlaro 2.3 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0079-01 63020-0079 Ixazomib Ninlaro 3.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 No Longer Used
63020-0079-02 63020-0079 Ixazomib Ninlaro 3.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0080-01 63020-0080 Ixazomib Ninlaro 4.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
63020-0080-02 63020-0080 Ixazomib Ninlaro 4.0 mg/1 Chemotherapy Proteasome Inhibitor 20S Oral Nov. 20, 2015 Oct. 31, 2023 No Longer Used
68727-0745-01 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
68727-0745-02 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
68727-0745-05 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
73358-0210-08 73358-0210 Docetaxel Anhydrous Docetaxel Anhydrous 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 17, 2022 In Use
73358-0210-16 73358-0210 Docetaxel Anhydrous Docetaxel Anhydrous 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 17, 2022 In Use
76388-0635-25 76388-0635 Chlorambucil Leukeran 2.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Feb. 13, 1985 Sept. 30, 2023 No Longer Used
76388-0635-50 76388-0635 Chlorambucil Leukeran 2.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Feb. 13, 1985 Oct. 31, 2017 No Longer Used
00703-4714-01 00703-4714 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous May 21, 2013 May 31, 2023 No Longer Used
00703-4714-71 00703-4714 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous May 21, 2013 May 31, 2023 No Longer Used
23155-0778-71 23155-0778 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0778-72 23155-0778 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
00069-0135-01 00069-0135 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0136-01 00069-0136 Bosutinib monohydrate, Bosutinib Bosulif 500.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0193-01 00069-0193 Bosutinib monohydrate, Bosutinib BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 18, 2017 In Use

Found 10,000 results in 6 milliseconds — Export these results